Why is Par Drugs & Che. falling/rising?

As of 23-Jul, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 114.73, down by 2.35 or 2.01%. Despite today's performance showing that the stock outperformed its sector by 5.25%, it is important to note that the stock has generated a significant negative return of -52.36% over the past year, with profits falling by 7.9%. The stock is trading at a discount compared to its peers, with a low Debt to Equity ratio and a favorable ROE of 13.8, indicating an attractive valuation. However, the company has shown poor long-term growth, with net sales and operating profit growth rates of only 10.39% and 6.96%, respectively, over the last five years, which may contribute to investor concerns.
In the broader market context, the stock has outperformed the Sensex in the short term, with a 1-week return of +19.09% compared to the benchmark's +0.03%. However, the year-to-date performance shows a stark contrast, with Par Drugs down 42.32% while the Sensex has gained 6.66%. This disparity highlights the challenges the company faces despite recent short-term gains. The negative results reported for the latest quarter, including a significant drop in PAT and net sales, further exacerbate the situation, leading to a cautious outlook from investors.